Skip to main content
. 2019 Mar 14;2019(3):CD013260. doi: 10.1002/14651858.CD013260
Mandatory items Optional items
Methods
Study design
  • Parallel‐group randomized controlled trial (RCT) i.e. people randomized to treatment

  • Within‐person RCT i.e. eyes randomized to treatment

  • Cluster RCT i.e. communities randomized to treatment

  • Cross‐over RCT

  • Other, specify

  • Exclusions after randomization

  • Losses to follow‐up

  • Number randomized/analyzed

  • How were missing data handled? e.g. available case analysis, imputation methods

  • Reported power calculation (Y/N), if yes, sample size and power

  • Unusual study design/issues

Eyes or
Unit of randomization/ unit of analysis
  • One eye included in study, specify how eye selected

  • Two eyes included in study, both eyes received same treatment, briefly specify how analyzed (best/worst/average/both and adjusted for within‐ person correlation/both and not adjusted for within person correlation) and specify if mixture of one eye and two eyes

  • Two eyes included in study, eyes received different treatments, specify if correct pair‐matched analysis done

Participants
Country
  • Setting

  • Ethnic group

  • Equivalence of baseline characteristics (Y/N)

Total number of participants This information should be collected for total study population recruited into the study. If these data are reported only for the people who were followed up, please indicate
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n= )
Comparator (n= )
  • Number of people randomized to this group

  • Drug (or intervention) name

  • Dose

  • Frequency

  • Route of administration

Outcomes
Primary and secondary outcomes, as defined in study reports
  • List outcomes

  • Adverse events reported (Y/N)

  • Length of follow‐up and intervals at which outcomes assessed

Planned/actual length of follow‐up